Last reviewed · How we verify
CDI-31244
CDI-31244 is a small molecule inhibitor targeting the SARS-CoV-2 main protease.
CDI-31244 is a small molecule inhibitor targeting the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | CDI-31244 |
|---|---|
| Also known as | CDI-31244 (non-nucleoside inhibitor or NNI), CC-31244 |
| Sponsor | Cocrystal Pharma, Inc. |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
CDI-31244 works by binding to the SARS-CoV-2 main protease, which is essential for the viral replication. This binding prevents the protease from processing the viral polyprotein, ultimately inhibiting the replication of the virus. As a result, CDI-31244 has the potential to treat COVID-19.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) (PHASE2)
- A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects (PHASE1)
- Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDI-31244 CI brief — competitive landscape report
- CDI-31244 updates RSS · CI watch RSS
- Cocrystal Pharma, Inc. portfolio CI